Effects of Eight Weeks High-Intensity Interval Training and Moderate-Intensity Continuous Training on Non-Invasive Liver Injury, Body Composition, and Metabolic Indices in Middle-Aged Women with MAFLD

Authors

1 - Razi University of Kermanshah

2 Kermanshah University of Medical Sciences

Abstract
Abstract

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most prevalent chronic liver disorder. Aerobic exercise is a key non-pharmacological strategy for MAFLD management, yet the impact of different training intensities remains unclear. This study investigated the effects of eight weeks of high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) on non-invasive liver indices, body composition, and metabolic markers in middle-aged women with MAFLD.

Methods: In this clinical trial, 41 women with MAFLD (41.39 ± 6.16 years; BMI: 32.14 ± 3.36 kg/m²) were randomly assigned to HIIT, MICT, or control groups. MICT involved 30–45 minutes at 60–70% heart rate reserve, while HIIT included 4–6 bouts of 30 seconds at 50–100–110% of maximal aerobic speed. Body composition (weight, BMI, BAI, ABSI), steatosis (HSI, FSI, LFS), fibrosis (NFS, NRS, FIB-4, FIB-5, APRI), and metabolic indices (LAP, CMI) were measured before and after the intervention. Statistical analyses included paired t-tests, one-way ANOVA, and GLMRM (p < 0.05).

Results: Both HIIT and MICT significantly reduced weight, BMI, BAI, and LFS. ABSI increased in control. HSI decreased following HIIT, while FSI decreased after MICT. Among fibrosis indices, only FIB-5 showed a significant reduction in MICT compared to HIIT, and NRS decreased in MICT compared to control. LAP decreased in both training groups relative to control, whereas CMI decreased only in MICT.

Conclusion: Although MICT demonstrated superiority in certain parameters, HIIT elicited comparable effects in a shorter duration and may represent an efficient strategy for the clinical management of MAFLD.

Keywords


1. Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023; 14:20420188221145549. DOI:10.1177/20420188221145549.
2. Polyzos SA, Kang ES, Tsochatzis EA, Kechagias S, Ekstedt M, Xanthakos S, et al. Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism. 2020; 113:154413. DOI: 10.1016/j.metabol.2020.154413.
3. Farahat TM, Ungan M, Vilaseca J, Ponzo J, Gupta PP, Schreiner AD, et al. The paradigm shifts from NAFLD to MAFLD: A global primary care viewpoint. Liver Int. 2022;42(6):1259–67. DOI:10.1111/liv.15188.
4. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. DOI:10.1002/hep.29367.
5. Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World J Gastroenterol. 2014;20(36):12945–55. DOI:10.3748/wjg. v20.i36.12945.
6. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. DOI:10.1002/hep.28431.
7. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8. DOI: 10.1016/j.dld.2009.08.002
11. Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Mobasseri M, Naghshi S, Ostadrahimi A. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study. Int J Clin Pract. 2021;75(6): e14131. DOI:10.1111/ijcp.14131.
12. Kolhe KM, Amarapurkar A, Parikh P, Chaubal A, Chauhan S, Khairnar H, et al. Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population. BMJ Open Gastroenterol. 2019;6(1): e000288. DOI:10.1136/bmjgast-2019-000288
17. Reinshagen M, Kabisch S, Pfeiffer AFH, Spranger J. Liver fat scores for noninvasive diagnosis and monitoring of nonalcoholic fatty liver disease in epidemiological and clinical studies. J Clin Transl Hepatol. 2023;11(5):1212–27. DOI:10.14218/JCTH.2022.00019.
20. Houttu V, Bouts J, Vali Y, Daams J, Grefhorst A, Nieuwdorp M, et al. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis. Front Endocrinol (Lausanne). 2022; 13:1032164. DOI:10.3389/fendo.2022.1032164.
34. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–9. DOI: 10.1016/j.jhep.2020.03.039.
37.Jafariyan S, Monazzami A, Nikousefat Z, Nobahar M, Yari K. Inflammatory and immune responses to a 3-day period of downhill running in active females. Cell Mol Biol (Noisy-le-grand) . 2017;63(7):76–83. DOI:10.14715/cmb/2017.63.7.13.
38. Amiri F, Moludi J, Jouybari TA, Ghasemi M, Sharifi M, Mahaki B, et al. Relationship between dietary inflammatory index and metabolic dysfunction-associated steatotic liver disease in children. Sci Rep. 2025;15(1):89690. DOI:10.1038/s41598-025-89690-x.
39. Astinchap A, Monazzami A, Rahimi Z, Rahimi M. The effect of moderate intensity endurance training on some fatty liver and metabolic indices in diabetic women with non-alcoholic fatty liver. Iran J Physiol Pharmacol. 2020; 4:49–58. Available from: http://ijpp.phypha.ir/article-1-439-en.html.
40. Hosseini M, Monazzami A. The effects of eight-week high-intensity intermittent training on body composition, aerobic and anaerobic performance, lipid profile and hematological indices in sedentary healthy overweight adolescent: A comparison of volume. Ann Mil Health Sci Res. 2021;19(1):112535. DOI:10.5812/amh.112535.
41. Abdelbasset WK, Tantawy SA, Kamel DM, Alqahtani BA, Elnegamy TE, Soliman GS, et al. Effects of high-intensity interval and moderate-intensity continuous aerobic exercise on diabetic obese patients with nonalcoholic fatty liver disease: A comparative randomized controlled trial. Medicine (Baltimore). 2020;99(10): e19471. DOI:10.1097/MD.0000000000019471.
42. Skrypnik D, Bogdanski P, Skrypnik K, Madry E, Karolkiewicz J, Szulinska M, et al. Influence of endurance and endurance-strength training on mineral status in women with abdominal obesity: A randomized trial. Medicine (Baltimore). 2019;98(12): e14909. DOI:10.1097/MD.0000000000014909.

Articles in Press, Accepted Manuscript
Available Online from 23 October 2019